Aktiesnakken — September 2016
-
Jeg er enig med Beskos her: https://play.borsen.dk/social/57c86599d99b63192e1f2f74
-
Det er ikke min strategi. Er lang og tager svingningerne med.
-
Det er jo heller ikke sikkert at Beskos får ret.
-
Min nye Genmab-analyse:
http://www.shareholders.dk/analyse/102396/fortsat-kursfest-i-genmab -
Min nye analyse på laks http://www.proinvestor.com/analyser
-
Samme historie som med kombien fra Sanofi og Zealand Pharma. Nu forlænges processen også for Novo.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
